Autres langues BrightPath Biotherapeutics Co., Ltd.

Actions

4594

JP3274140007

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
59 ^JPY	0,00 %		+5,36 %	-32,18 %

2022	Brightpath Biotherapeutics annonce des données précliniques sur le BP1209	CI
2018	Brightpath Biotherapeutics Co., Ltd. annonce les résultats des bénéfices consolidés pour le semestre clos le 30 septembre 2018 ; fournit des prévisions de bénéfices consolidés pour l'année se terminant le 31 mars 2019.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	30/11
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	14/11
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	19/09/22
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	14/04/22
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	14/04/22
BrightPath Biotherapeutics : Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022	13/04/22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	13/04/22
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	13/04/22
BrightPath Biotherapeutics : Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022	11/04/22
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022	11/04/22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	01/02/22
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	14/01/22
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	23/04/20
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	07/04/20
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	09/11/18
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	10/08/18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	11/05/18
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	14/02/18
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	08/12/17
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	22/11/17

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BrightPath Biotherapeutics Co., Ltd.

Actions

4594

JP3274140007

Autres langues

Filtres